Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Vasculitis 1Urogenital Neoplasms 1Stroke 1Lung Neoplasms 1Inflammation 1Depressive Disorder, Major 1Depression 1Colitis 1Cognitive Dysfunction 1Carcinoma, Non-Small-Cell Lung 1Aneurysm 1

Interventions

mazdutide 1lithium sulfate 1lime 1fasudil 1blueberry extract 1Walking 1Transcranial Magnetic Stimulation 1Transcranial Direct Current Stimulation 1Therapeutics 1Tablets 1Radiotherapy 1Patient Reported Outcome Measures 1Organization and Administration 1Neuropsychological Tests 1Modafinil 1Methods 1Metformin 1Memantine 1Low-Level Light Therapy 1Lithium 1Infliximab 1Drug Therapy 1Data Collection 1Cognitive Behavioral Therapy 1Chemoradiotherapy 1Accidental Falls 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Cognitive Dysfunction × Infliximab × Clear all
NCT06136546 2025-05-07

Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab

Massachusetts General Hospital

Phase 2 Recruiting
100 enrolled

Depression, Depressive Disorder, Major, Inflammation, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡